AGTRAP as a Radioligand Therapy Target
AGTRAP, angiotensin II receptor associated protein, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, AGTRAP staining is highest in prostate cancer (100% of samples positive), cervical cancer (100% of samples positive) and thyroid cancer (100% of samples positive). Published literature reports that AGTRAP internalizes after ligand binding, which helps retain a radionuclide inside tumor cells. Clinical status: Discovery-stage (no clinical drug program).
Is AGTRAP a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in prostate cancer, 100% of samples positive.
- ✅ Internalization: Reported to internalize, which favors radionuclide retention.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
AGTRAP expression in cancer
Protein expression of AGTRAP across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Prostate Cancer | 0.97 | High | 100% |
| Cervical Cancer | 0.97 | High | 100% |
| Thyroid Cancer | 0.92 | High | 100% |
| Kidney Cancer | 0.83 | High | 100% |
| Testicular Cancer | 0.83 | High | 100% |
| Melanoma | 0.81 | High | 100% |
| Endometrial Cancer | 0.78 | High | 100% |
| Colorectal Cancer | 0.76 | High | 100% |
| Lung Cancer | 0.76 | High | 100% |
| Pancreatic Cancer | 0.75 | High | 92% |
| Breast Cancer | 0.69 | High | 100% |
| Head and Neck Cancer | 0.67 | High | 100% |
| Neuroendocrine Tumors | 0.67 | High | 100% |
| Ovarian Cancer | 0.64 | High | 83% |
| Gastric Cancer | 0.61 | High | 91% |
| Bladder Cancer | 0.61 | High | 82% |
| Skin Cancer | 0.55 | High | 82% |
| Liver Cancer | 0.42 | Medium | 64% |
| Glioma | 0.40 | Medium | 70% |
| Lymphoma | 0.19 | Low | 25% |
Is AGTRAP internalized?
Yes. AT1R-associated protein (ATRAP/Agtrap) binds to AT1R, promotes its internalization, and inhibits Ang II signaling.
Sources: PMID 41291382 · PMID 36060798 · PMID 34642449 · PMID 32112267 · PMID 30977419. AI-extracted from abstracts, so verify before citing.
AGTRAP clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for AGTRAP yet. Search ClinicalTrials.gov for AGTRAP trials.
AGTRAP normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See AGTRAP in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
AGTRAP gene essentiality (DepMap)
CRISPR knockout effect across 1257 cancer cell lines: 0.06 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related prostate cancer radioligand targets
PSMA (FOLH1) · HER3 (ERBB3) · c-MET (MET) · EGFR · EPCAM · FAP · B7-H3 (CD276) · STEAP2
See all radioligand therapy targets in prostate cancer.
See how AGTRAP ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.